EUVIMEDTutustu EUVIMEDiin
Open access · CC BY 4.0

Prospective case‐control cohort analysis of two‐day/two‐stage pelvic exenteration surgery: Safety, feasibility, acceptability and medium‐term outcomes

Charles T West iD, Yousif Salem, Siddharth Jain, Lewis Matthews, Julian Smith, Marios Nicolaou, Hideaki Yano, Malcolm A West, Alex H Mirnezami

Colorectal Disease · 2026

DOI: 10.1111/codi.70353 ↗

At a glance

Journal article in Colorectal Disease, 2026. Written by Charles T West and 8 co-authors. Institution: Southampton Complex Cancer and Exenteration Team, University Hospital Southampton, Southampton, UK. Major MEDLINE topics: Pelvic Exenteration. 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: Bowel Research UK, PLANETS Cancer Charity, Penguins Against Cancer.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Aim

Pelvic exenteration (PE) is the only curative option for extensive pelvic cancers. Advances have facilitated increasingly complex resectional and reconstructive components, including per‐operative oncological adjuncts such as intraoperative radiotherapy. Cumulatively, these components increase operative duration beyond what is feasible within a single conventional operating day. Two‐day/two‐stage PE addresses this, but little is known about this approach. This study aims to evaluate the feasibility, safety and medium‐term outcomes of a two‐day/two‐stage PE.

Method

Consecutive patients (2010–2025) from a prospectively maintained high‐volume PE unit database ( n = 373) undergoing two‐day/two‐stage PE were compared against a matched control cohort of single‐day cases lasting ≥15 h. EQ5D‐5L and decision regret scores were longitudinally collected after 2021. Surgical, oncological and health‐related quality‐of‐life outcomes were evaluated.

Results

Twenty‐seven patients underwent two‐day/two‐stage PE, and 38 had one‐day PE; more anal cancers were in the two‐day/two‐stage group ( p = 0.012); median follow‐up was 24.2 months. No 90‐day mortalities occurred; 3‐year overall survival was 54.4% for two‐day/two‐stage PE and 70.5% for one‐day PE ( p = 0.31); and R0‐resection rates were 82% and 76%, respectively ( p = 0.76). Major morbidity occurred in 56% and 47% ( p = 0.62), with a median length of stay of 37 and 27 days ( p = 0.07) and intensive care days of 5 and 3 ( p = 0.08). 12‐month EQ5D‐5L utility scores were 0.79 and 0.81 ( p = 0.96), with low 12‐month decision regret in both groups ( p = 0.15).

Conclusion

Two‐day/two‐stage PE is safe and feasible, potentially representing the only option for highly selected patients needing high‐complexity PE with multiple components. Although equivalent R0‐resections were obtained, medium‐term oncological outcomes were poorer in patients undergoing two‐day/two‐stage interventions.

Subjects

MeSH terms (MEDLINE)

Pelvic ExenterationHumansFemaleFeasibility StudiesMiddle AgedMaleAgedCase-Control StudiesProspective StudiesQuality of LifeTreatment OutcomeOperative TimeAdultLength of StayPostoperative ComplicationsAged, 80 and over

Author keywords

complicationscritical carehealth‐related quality of lifepelvic exenteration

Authors and institutions

  • Southampton Complex Cancer and Exenteration Team, University Hospital Southampton, Southampton, UK.
  • Department of Academic Surgery, Cancer Sciences, University of Southampton, Southampton, UK.
  • The Shackleton Department of Anaesthesia, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Urology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Department of Plastic and Reconstructive Surgery, University Hospital Southampton, Southampton, UK.
  • NIHR Southampton Biomedical Research Centre, Perioperative Medicine and Critical Care Theme, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.

ORCID profiles: Charles T West

Funding

  • Bowel Research UK
  • PLANETS Cancer Charity
  • Penguins Against Cancer

Cite

APA

West, C. T., Salem, Y., Jain, S., Matthews, L., Smith, J., Nicolaou, M., Yano, H., West, M. A., & Mirnezami, A. H. (2026). Prospective case‐control cohort analysis of two‐day/two‐stage pelvic exenteration surgery: Safety, feasibility, acceptability and medium‐term outcomes. Colorectal Disease. https://doi.org/10.1111/codi.70353

Vancouver

West CT, Salem Y, Jain S, Matthews L, Smith J, Nicolaou M, et al. Prospective case‐control cohort analysis of two‐day/two‐stage pelvic exenteration surgery: Safety, feasibility, acceptability and medium‐term outcomes. Colorectal Disease. 2026. doi:10.1111/codi.70353

BibTeX
@article{West2026,
  author = {West, Charles T and Salem, Yousif and Jain, Siddharth and Matthews, Lewis and Smith, Julian and Nicolaou, Marios and Yano, Hideaki and West, Malcolm A and Mirnezami, Alex H},
  title = {Prospective case‐control cohort analysis of two‐day/two‐stage pelvic exenteration surgery: Safety, feasibility, acceptability and medium‐term outcomes},
  journal = {Colorectal Disease},
  year = {2026},
  doi = {10.1111/codi.70353}
}
Start for free →